提升的组织因子通路抑制剂在COVID-19中延迟了血栓生成,但与临床结果无关
Alicia S Eustes1, Meena Kumari Palani Kumar1, Julie A Peterson2
1Department of Internal Medicine, University of Iowa, Iowa City, IA.
Blood vessels, thrombosis & hemostasis
|August 6, 2025
概括
在COVID-19患者中血组织因子通路抑制剂 (TFPI) 的升高延迟了血栓生成和血栓形成. 然而,这种TFPI增加与血栓形成或住院患者的不良临床结果无关.
科学领域:
- 凝血科学是一门凝血科学.
- 传染病病理学 传染病病理学
- 心血管研究的心血管研究.
背景情况:
- 组织因子通路抑制剂 (TFPI) 的血水平在COVID-19患者中升高.
- 在COVID-19相关的凝血病中TFPI的具体作用尚未完全理解.
- 了解TFPI的贡献对于管理血栓性并发症至关重要.
研究的目的:
- 为了确定TFPI对COVID-19患者血栓生成的贡献.
- 评估TFPI水平与临床结果 (包括血栓形成) 之间的关联.
- 调查TFPI对急性COVID-19中的凝血动态的影响.
主要方法:
- 分析了因急性COVID-19住院的成年患者的血液样本.
- 使用酶相关免疫吸收试验 (ELISA) 测量血TFPI.
- 评估具有和没有TFPI中和抗体的血栓生成潜力.
- 在全血样本上进行的血栓形成显微镜 (TEG).
主要成果:
- 与健康个体相比,COVID-19患者表现出高血TFPI.
- 在COVID-19中,血栓生成增加,但启动 (延迟时间) 被延迟.
- TFPI中和缩短了COVID-19患者的滞后时间,使对照组的差异正常化.
- TFPI与延迟的血栓生成和凝块形成的启动正相关.
- TFPI水平与30天死亡率,血栓形成或其他不良结果无关.
结论:
- 在COVID-19中血TFPI升高延迟了血栓生成和血栓启动.
- 尽管推迟了凝血开始,但TFPI与住院COVID-19患者的血栓形成无关.
- 在COVID-19凝血病中TFPI的作用似乎很复杂,主要影响启动,而不是促进血栓形成.
相关概念视频
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
909
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
909
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
36
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
36
Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
Venous Thrombosis I: Introduction
41
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
41


